TrialSignal
Clinical trial intelligence report
A Long-term, Randomized, Open-labeled, Parallel-group Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT01593137-Jul 28, 2026
NCT ID
NCT01593137
Status
WITHDRAWN
Phase
PHASE4
Sponsor
Fundación Fernández-Cruz
Executive brief
Investment-Ready Snapshot
A Long-term, Randomized, Open-labeled, Parallel-group Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes is a PHASE4 clinical asset sponsored by Fundación Fernández-Cruz in Type 2 Diabetes. SEO and diligence focus: Liraglutide + metformin, Glimepiride + metformin, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01593137
Indication
Type 2 Diabetes
Modality
small molecule
Target
Liraglutide + metformin, Glimepiride + metformin
Intervention
Liraglutide + metformin, Glimepiride + metformin
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.